Ser556
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser556  -  SNCAIP (human)

Site Information
AQKSEGKsLPssPss   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 469990

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 5 ) , western blotting ( 5 )
Disease tissue studied:
acute lymphocytic leukemia ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 5 )
Kinases, in vitro:
GSK3B (human) ( 5 )

Downstream Regulation
Effects of modification on SNCAIP:
molecular association, regulation ( 5 ) , protein processing ( 5 ) , protein stabilization ( 5 )
Induce interaction with:
14-3-3 beta (human) ( 5 )

References 

1

Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169
21552520   Curated Info

2

Possemato A (2006) CST Curation Set: 1732; Year: 2006; Biosample/Treatment: cell line, NCI-H128/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

3

Possemato A (2006) CST Curation Set: 1733; Year: 2006; Biosample/Treatment: cell line, NCI-H446/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

4

Possemato A (2006) CST Curation Set: 1734; Year: 2006; Biosample/Treatment: cell line, NCI-H446/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

5

Avraham E, et al. (2005) Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J Biol Chem 280, 42877-86
16174773   Curated Info